Data Foundry

Medical device recalls 2021

Philips Respironics V60 Plus Ventilator with Software Versions 3 — Class I medical device recall Z-2074-2021

Ongoing recall by Respironics California, LLC, reported 2021-07-28, distributed nationwide. It has been identified that ventilators equipped with High Flow Therapy (Software Versions 3.00 and 3.10), tha

Recall numberZ-2074-2021
Product typeMedical device
ClassificationClass I
StatusOngoing
Voluntary or mandatedVoluntary
Recalling firmRespironics California, LLC, Carlsbad, CA, United States
Recall initiated2021-06-18
Classified2021-07-21
Reported by FDA2021-07-28
DistributedNationwide (US)
Countries outside the USAE, AR, AT, AU, BE, CA, CH, CL, CN, CO, CZ, DE, DK, ES, FI, FR, GB, GR, HK, ID, IE, IN, IS, IT, JO, KE, KW, LB, LV, MA, MT, MX, MY, NG, NL, NO, NZ, PH, PL, PT, QA, SA, SE, SG, SI, TH, ZA
Quantity23,115 systems
Reason classessoftware
UPC / GTIN / UDI-DI00884838089280, 00884838090996
Model numbersV60

Product

Philips Respironics V60 Plus Ventilator with Software Versions 3.00 and 3.10. The Respironics V60/V60 Plus Ventilator is an assist ventilator and is intended to augment patient breathing. It is intended for spontaneously breathing individuals who require mechanical ventilation: patients with respiratory failure, chronic respiratory insufficiency, or obstructive sleep apnea in a hospital or other institutional settings under the direction of a physician.

Reason for recall

It has been identified that ventilators equipped with High Flow Therapy (Software Versions 3.00 and 3.10), that includes a designed safety mechanism that limits the amount of pressure that can be delivered to a patient, in situations where the system pressure reaches the maximum limit and sounds the "Cannot Reach Target Flow" alarm , the system will reduce pressure and simultaneously decreasing the flow rate to a level below what was set by the clinicians. If the reason for the increase in pressure is not resolved, the ventilator will continue to provide the lower flow rate, which result in patients experiencing oxygen desaturation which can be characterized as moderate or severe hypoxemia.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/Z-2074-2021. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.